Nazartinib
Showing 1 - 9 of 9
Non Small Cell Lung Cancer Trial in Worldwide (Capmatinib, Nazartinib)
Terminated
- Non Small Cell Lung Cancer
- Capmatinib
- Nazartinib
-
Boston, Massachusetts
- +18 more
Jul 20, 2022
Advanced Solid Tumors Which Are cMET-dependent Trial in Worldwide (Capmatinib, Nazartinib, Gefitinib)
Recruiting
- Advanced Solid Tumors Which Are cMET-dependent
- Capmatinib
- +3 more
-
Boston, Massachusetts
- +12 more
Jan 27, 2023
Advanced NSCLC Trial in Worldwide (EGF816)
Active, not recruiting
- Advanced Non-small Cell Lung Cancer
-
Boston, Massachusetts
- +13 more
Oct 21, 2022
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma Trial in Worldwide (PDR001, ACZ885, CJM112)
Completed
- Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
- PDR001
- +4 more
-
Baltimore, Maryland
- +22 more
Mar 15, 2022
Carcinoma, Non-small Cell Lung Trial (EFG816, erlotinib or gefitinib)
Withdrawn
- Carcinoma, Non-small Cell Lung
- EFG816
- erlotinib or gefitinib
- (no location specified)
Nov 21, 2019
EGFR-mutant NSCLC Trial in Worldwide (EGF816, trametinib, ribociclib)
Active, not recruiting
- EGFR-mutant Non-small Cell Lung Cancer
- EGF816
- +5 more
-
Toronto, Ontario, Canada
- +10 more
Dec 5, 2022
